CM Life Sciences, Inc.

This is a routine annual meeting for a company that came public via a SPAC, and every proposal passed. The one substantive data point is the say-on-pay vote: 1,471,593 against out of roughly 24.2 million votes cast on that proposal is about 6% opposition, which is modest but higher than the near-unanimous auditor ratification, and shareholders chose annual rather than triennial future votes. No financial results, transactions or capital changes are disclosed.

This is not a SPAC business combination and carries no redemption right. The document states plainly that the issuance proposals are put to stockholders only to comply with listing rule 5635 of the Nasdaq Stock Market, and that stockholders are not being asked to approve the acquisition or the private placement financing themselves. A reader who treats a tier-1 filing under a SPAC's CIK as that SPAC's own deal will mis-attribute this one: the vehicle had already completed its combination and is here acting as an operating company buying a target.

The consideration to OPKO is $150 million in cash at closing, subject to adjustment, plus 80 million shares of Class A common stock, plus up to $150 million more payable in cash or shares if revenue-based milestones are met for the fiscal years ending December 31, 2022 and December 31, 2023. No trust and no redemption right stands behind it: the cash is funded in part from a PIPE of 50 million shares of Class A common stock at $4.00 per share, $200 million gross before fees and expenses. Goldman Sachs's written opinion is dated January 14, 2022.

The consideration is an election with a hard cap and a fixed conversion price: a Sema4 stockholder electing cash takes a pro rata share of Closing Available Cash but never more than its total outstanding shares multiplied by the Per Share Amount, and whatever is not taken in cash converts into Company Class A common stock at that same Per Share Amount divided by $10.00. Sema4 Class B stock first converts into one one-hundredth of a share of Class A. The earnout includes Earnout RSUs, which vest and are not outstanding shares at the closing.

The stock leg is computed off a fixed $10.00 divisor rather than a market price: each Sema4 stockholder receives shares equal to its total shares times the Per Share Amount, less any cash it elects, divided by $10.00 — so electing cash reduces the share count at that fixed rate. On top sits an earnout capped in aggregate at 11% of the Earn-Out Total Outstanding Shares, released as 3.66%, 3.67% and 3.67% on three Triggering Events, each of which may occur only once. Sema4 Class B shares first convert into one one-hundredth of a Class A share each.

What changed: 8-K of GeneDx Holdings Corp. Item 2.02 (results of operations and financial condition): on August 3, 2026 the Company issued a press release and will hold a conference call announcing its financial results for the quarter ended June 30, 2026. The press release and an earnings presentation are furnished as Exhibits 99.1 and 99.2. The information furnished with Item 2.02, including both exhibits, shall not be deemed filed for Section 18 purposes nor incorporated by reference. Signed by CEO Katherine Stueland. Why it matters: Routine quarterly earnings furnishing; the report states no figure. Item 9.01 lists no cover-page Inline XBRL exhibit, unlike the other earnings 8-Ks filed the same week.

What changed: The successor to CM Life Sciences, Inc. filed its Q2 2026 10-Q reporting cash, cash equivalents and available-for-sale marketable securities of $132.5 million at June 30, 2026, which it says gives at least twelve months of liquidity. Class A shares outstanding rose to 29,803,164 from 29,245,296 at December 31, 2025 and total liabilities to $237.3 million from $215.5 million. Operating activities used $61.4 million of cash in the six months, driven by a net loss of $81.1 million. Contingent consideration of up to $10.5 million is payable if Fabric Genomics reaches $6.0 million of gross revenue. Why it matters: Routine quarterly reporting for a completed de-SPAC — no trust, redemption right or deadline remains. The number that matters is runway: $132.5 million on hand against $61.4 million of operating cash burn in six months is roughly a year of cover on the current rate, which is why management flags possible future sales of common or preferred equity or convertible debt. Any of those routes dilutes the 29.8 million shares outstanding, and the Fabric Genomics earnout adds up to $10.5 million payable in cash or stock on top.